Head and Neck Survivorship: Salivary Cancer

Patient presents:
- Treated with surgery with/without radiotherapy and
- 4 years disease FREE from LAST treatment and NED

**SURVEILLANCE**
- Physical exam within 6-12 months of transition to HNSVC with:
  - Chest x-ray
  - CT of head and neck (or MRI if previous imaging was MRI) if less than or equal to 5 years from completion of treatment, then
- Physician exam annually with:
  - Chest x-ray
  - CT of head and neck (or MRI, per baseline imaging study) through 5 years from the end of treatment

Consider:
- Annual audiogram
- Xerostomia assessment
- Dental/osteoradionecrosis assessment
- T4 and TSH annually if treated with radiation therapy
- Dysphagia assessment
- Speech pathology assessment
- Lymphedema assessment
- Neurocognitive dysfunction assessment

**RISK REDUCTION/EARLY DETECTION**
- Patient education, counseling and screening:
  - Colorectal cancer screening (See Colorectal Cancer Screening Algorithm)
  - Prostate cancer screening (for men)\(^1\)
  - Breast cancer screening (See Breast Cancer Screening Algorithm) (for women)
  - Gynecologic screening (See Gynecology Screening Algorithm) (for women)
  - Lung cancer screening (See Lung Cancer Screening Algorithm)
  - Diet/weight management
  - Exercise/activity (See Physical Activity Algorithm)
  - Tobacco cessation (See Tobacco Cessation Algorithm)
  - Sun exposure/skin cancer screening (See Skin Cancer Screening Algorithm)
  - Limit alcohol

**PSYCHOSOCIAL FUNCTIONING**
- Assess for:
  - Anxiety/depression
  - Financial stressors
  - Body image
  - Social image

**DISPOSITION**
- New primary or recurrent cancer?
  - Yes: Return to primary treating physician
  - No: Continue survivorship monitoring

---

\(^1\)Based on American Cancer Society Prostate Cancer Screening Guidelines

NED = no evidence of disease
HNSVC = Head and Neck Survivorship clinic

---

Copyright 2017 The University of Texas MD Anderson Cancer Center

Approved by the Executive Committee of the Medical Staff on 01/31/2017
SUGGESTED READINGS


Support Care Cancer, 16(2), 171-179. doi: http://dx.doi.org/10.1007/s00520-007-0300-5


http://dx.doi.org/10.1002/hed.1049


doi: http://dx.doi.org/10.1016/j.ejca.2005.02.023


http://archotol.ama-assn.org/cgi/reprint/127/7/884


doi: http://dx.doi.org/10.1200/JCO.2005.05.419


DEVELOPMENT CREDITS

This practice consensus algorithm is based on majority expert opinion of the Survivorship Head and Neck Faculty at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following medical, radiation and surgical oncologists.

- Katherine Bell, ACNS
- Mark Chambers, MD
- Eduardo Díaz Jr., MD
- Bita Esmaeili, MD
- Michelle Cororve Fingret, Ph.D
- Steven Frank MD
- Paul Gidley, MD
- Ann Gillenwater, MD
- Dan Gombos, MD
- Ehab Hanna, MD
- Amy Hessel, MD
- Theresa Hofstede, MD
- Shonice Holdman, BA
- Kate Hutcheson, MD
- Michael Kupferman, MD
- Stephen Lai, MD
- Jan Lewin, MD
- Carol Lewis, MD
- Paula Lewis-Patterson, DNP, RN, NEA-BC
- Guojun Li, MD
- Clemente Logrionio Jr., BSN, RN-BC
- Charles Lu MD
- Jeffrey Myers, MD
- Kristen Pytynia, MD, MPH
- Charles Schreiner, ACNP
- Erich Sturgis MD
- Randal Weber, MD
- Mark Zafereo, MD

*Core Development Team Lead
Clinical Effectiveness Development Team